Do we need new antibiotics?

Clinical Microbiology and Infection

Volumn 22, Issue 5, 2016, Pages 408-415

  Rolain, J M ^a   Abat, C ^a   Jimeno, M T ^a   Fournier, P E ^a   Raoult, D ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Antimicrobial resistance; Old antibiotics

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; EUROPE; GREECE; HUMAN; ITALY; KLEBSIELLA PNEUMONIAE; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; ROMANIA; BACTERIAL INFECTIONS; INCIDENCE; MICROBIOLOGY; PREVALENCE; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; HUMANS; INCIDENCE; PREVALENCE; TREATMENT OUTCOME;

EID: 84964664182     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.03.012     Document Type: Review

References (33)

1. Bush K., Courvalin P., Dantas G., Davies J., Eisenstein B., Huovinen P., et al. Tackling antibiotic resistance. Nat Rev Microbiol 2011, 9:894-896.
2. Lushniak B.D. Antibiotic resistance: a public health crisis. Public Health Rep 2014, 129:314-316.
3. Ventola C.L. The antibiotic resistance crisis: part 1: causes and threats. Pharm Ther 2015, 40:277-283.
4. Ventola C.L. The antibiotic resistance crisis: part 2: management strategies and new agents. Pharm Ther 2015, 40:344-352.
5. Donadio S., Monciardini P., Sosio M. Polyketide synthases and nonribosomal peptide synthetases: the emerging view from bacterial genomics. Nat Prod Rep 2007, 24:1073-1109.
6. Meier J.L., Burkart M.D. The chemical biology of modular biosynthetic enzymes. Chem Soc Rev 2009, 38:2012-2045.
7. Lewis K. Platforms for antibiotic discovery. Nat Rev Drug Discov 2013, 12:371-387.
8. Lewis K. Antibiotics: recover the lost art of drug discovery. Nature 2012, 485(7399):439-440.
9. Kaeberlein T., Lewis K., Epstein S.S. Isolating "uncultivable" microorganisms in pure culture in a simulated natural environment. Science 2002, 296(5570):1127-1129.
10. D'Costa V.M., McGrann K.M., Hughes D.W., Wright G.D. Sampling the antibiotic resistome. Science 2006, 311(5759):374-377.
11. D'Costa V.M., King C.E., Kalan L., Morar M., Sung W.W., Schwarz C., et al. Antibiotic resistance is ancient. Nature 2011, 477(7365):457-461.
12. Bhullar K., Waglechner N., Pawlowski A., Koteva K., Banks E.D., Johnston M.D., et al. Antibiotic resistance is prevalent in an isolated cave microbiome. PLOS One 2012, 7(4):e34953.
13. Toleman M.A., Spencer J., Jones L., Walsh T.R. BlaNDM-1 is a chimera, likely constructed in Acinetobacter baumannii. Antimicrob Agents Chemother 2012, 56:2773-2776.
14. Andersson D.I., Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance?. Nat Rev Microbiol 2010, 8:260-271.
15. Rolain J.M., Roch A., Castanier M., Papazian L., Raoult D. Acinetobacter baumannii resistant to colistin with impaired virulence: a case report from France. J Infect Dis 2011, 204:1146-1147.
16. Hraiech S., Roch A., Lepidi H., Atieh T., Audoly G., Rolain J.M., et al. Impaired virulence and fitness of a colistin-resistant clinical isolate of Acinetobacter baumannii in a rat model of pneumonia. Antimicrob Agents Chemother 2013, 57:5120-5121.
17. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994, 264(5157):375-382.
18. Kristinsson K.G. Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci. Microb Drug Resist 1997, 3:117-123.
19. Arason V.A., Gunnlaugsson A., Sigurdsson J.A., Erlendsdottir H., Gudmundsson S., Kristinsson K.G. Clonal spread of resistant pneumococci despite diminished antimicrobial use. Microb Drug Resist 2002, 8:187-192.
20. Rolain J.M., Abat C., Brouqui P., Raoult D. Worldwide decrease in methicillin-resistant Staphylococcus aureus: do we understand something?. Clin Microbiol Infect 2015, 21:515-517.
21. de Kraker M.E., Davey P.G., Grundmann H. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med 2011, 8:e1001104.
22. Abat C., Raoult D., Rolain J.M. Low level of resistance in enterococci isolated in four hospitals, Marseille, France. Microb Drug Resist 2015 Aug 6, 10.1089/mdr.2015.0121.
23. ECDC Antimicrobial resistance surveillance in Europe-Annual report 2013 2013, http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf.
24. Falagas M.E., Tansarli G.S., Karageorgopoulos D.E., Vardakas K.Z. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 2014, 20:1170-1175.
25. Vardakas K.Z., Rafailidis P.I., Konstantelias A.A., Falagas M.E. Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug?. J Infect 2013, 66:401-414.
26. Vardakas K.Z., Matthaiou D.K., Falagas M.E., Antypa E., Koteli A., Antoniadou E. Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit. J Infect 2015, 70:592-599.
27. Dubourg G., Okdah L., Le Page S., Rolain J.M., Raoult D. In vitro activity of "old antibiotics" against highly resistant Gram-negative bacteria. Int J Antimicrob Agents 2015, 46:718-720.
28. Cassir N., Rolain J.M., Brouqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol 2014, 5:551.
29. Petrosillo N., Ioannidou E., Falagas M.E. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008, 14:816-827.
30. Sirijatuphat R., Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 2014, 58:5598-5601.
31. Brouqui P., Aubry C., Million M., Drancourt M., Raoult D. Totally resistant tuberculosis: will antileprosy drugs be helpful?. Int J Antimicrob Agents 2013, 42:584-585.
32. Pulcini C., Bush K., Craig W.A., Frimodt-Moller N., Grayson M.L., Mouton J.W., et al. Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis 2012, 54:268-274.
33. Abat C., Chaudet H., Colson P., Rolain J.M., Raoult D. Real-time microbiology laboratory surveillance system to detect abnormal events and emerging infections, Marseille, France. Emerg Infect Dis 2015, 21:1302-1310.